Background/Aims: In hemodialysis patients, there is a marked inter-individual variability in the pharmacokinetics of vancomycin. This retrospective study was carried out to design a model describing the parameters that may influence the trough concentrations of vancomycin (TCV) in hemodialysis patients. Methods: A Bayesian model was constructed from data obtained during 314 hemodialysis sessions performed in 31 hemodialysis patients receiving vancomycin. The model's validity was assessed by goodness of fit. A bootstrap resampling method was used to calculate bias and accuracy for 80 predicted and observed TCV. Results: A total of 31 patients underwent dialysis 3 times a week for a mean duration of 4 h. Their mean age was 69 ± 12 years. The vancomycin infusion was started 30 min before the scheduled end of the dialysis session at a flow rate of 1,000 mg/h. The mean TCV of the study population was 16.1 ± 3.2 mg/l. The area under receiver operating characteristic curve of the constructed model was 95.2%. In the validation sample (80 randomly selected TCV), the observed mean TCV was 15.8 ± 3.6 mg/l, whereas the mean TCV predicted by the model was 15.7 ± 3.0 mg/l. If the mean bias was low between the predicted and observed TCV (-0.1 mg/l), SD was high (3.43 mg/l). The variables most closely linked to TCV were in descending order: weight after dialysis, weight before dialysis, the dose of vancomycin administered during the previous dialysis session and creatinine concentration before dialysis. Conclusion: This simple model describes patient-related and dialysis-related parameters that mainly influence TCV. Before its use in clinical practice, this model should be validated prospectively.

Keywords:
Hemodialysis, Renal failure, Statistics, Pharmacokinetics
1.
Vandecasteele SJ, Boelaert JR, De Vriese AS: Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 2009;4:1388-1400.
2.
Sarnak MJ, Jaber BL: Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000;58:1758-1764.
3.
de Francisco AL, Kim J, Anker SD, Belozeroff V, Canaud B, Chazot C, Drüeke TB, Eckardt KU, Floege J, Kronenberg F, Macdougall IC, Marcelli D, Molemans B, Passlick-Deetjen J, Schernthaner G, Stenvinkel P, Wheeler DC, Fouqueray B, Aljama P: An epidemiological study of hemodialysis patients based on the European Fresenius medical care hemodialysis network: results of the ARO study. Nephron Clin Pract 2011;118:c143-c154.
4.
Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW: Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis 2004;44(5 suppl 2):16-21.
5.
Pallotta KE, Manley HJ: Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 2008;21:63-70.
6.
Panais R, Hirsch DJ, Dipchand C, Storsley L, Finkle SN: A protocolized approach to vancomycin dosing in conventional hemodialysis. J Nephrol 2010;23:569-574.
7.
Launay-Vacher V, Izzedine H, Mercadal L, Deray G: Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6:313-316.
8.
Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, Stryjewski ME, Reller LB, Schulman KA, Corey GR, Fowler VG Jr: Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005;26:534-539.
9.
Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-876.
10.
Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, Howden BP, Paterson DL: Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 2013;43:110-119.
11.
Ye ZK, Tang HL, Zhai SD: Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One 2013;8:e77169.
12.
Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA: Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005;46:681-687.
13.
Scott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA: Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997;17:256-262.
14.
Ducher M, Kalbacher E, Combarnous F, Finaz de Vilaine J, McGregor B, Fouque D, Fauvel JP: Comparison of a Bayesian network with a logistic regression model to forecast IgA nephropathy. BioMed Res Int 2013;2013:686150.
15.
Lalande L, Bourguignon L, Carlier C, Ducher M: Bayesian networks: a new method for the modeling of bibliographic knowledge: application to fall risk assessment in geriatric patients. Med Biol Eng Comput 2013;51:657-664.
16.
Sakai S, Kobayashi K, Nakamura J, Toyabe S, Akazawa K: Accuracy in the diagnostic prediction of acute appendicitis based on the Bayesian network model. Methods Inf Med 2007;46:723-726.
17.
Wang CP, Ghosh M: A Kullback-Leibler divergence for Bayesian model diagnostics. Open J Stat 2011;1:172-184.
18.
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
19.
El Nekidy WS, El-Masri MM, Umstead GS, Dehoorne-Smith M: Factors influencing vancomycin loading dose for hospitalized hemodialysis patients: prospective observational cohort study. Can J Hosp Pharm 2012;65:436-442.
20.
Burnside ES, Davis J, Chhatwal J, Alagoz O, Lindstrom MJ, Geller BM, Littenberg B, Shaffer KA, Kahn CE Jr, Page CD: Probabilistic computer model developed from clinical data in national mammography database format to classify mammographic findings. Radiology 2009;251:663-672.
21.
Zhao D, Weng C: Combining PubMed knowledge and EHR data to develop a weighted Bayesian network for pancreatic cancer prediction. J Biomed Inform 2011;44:859-868.
22.
Ducher M, Mounier-Véhier C, Lantelme P, Vaisse B, Baguet JP, Fauvel JP: Reliability of a Bayesian network to predict an elevated aldosterone-to-renin ratio. Arch Cardiovasc Dis 2015;108:293-299.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.